Experienced in Orchiectomy

Dr. Michael E. Hurwitz

Oncology
Yale University
20 York St, 
New Haven, CT 
Offers Telehealth
Experienced in Orchiectomy
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Hurwitz is an Oncologist in New Haven, Connecticut. Dr. Hurwitz is rated as an Experienced provider by MediFind in Orchiectomy. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Adult Soft Tissue Sarcoma, and Orchiectomy.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Orchiectomy.

Specialties
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Bridgeport Hospital
Greenwich Hospital Association -
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Enrollment Status: Completed
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer
A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: November 21, 2024
Intervention Type: Drug
Study Drug: Tumor infiltrating lymphocytes (TIL) LN-145
Study Phase: Phase 2
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor
A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor
Enrollment Status: Withdrawn
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pembrolizumab+Ramucirumab
Study Phase: Phase 2
View 5 Less Clinical Trials

49 Total Publications

Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.
Journal: Journal for immunotherapy of cancer
Published: August 27, 2025
Similar Doctors
Advanced in Orchiectomy
Dr. Daniel P. Petrylak
Oncology | Hematology Oncology
Advanced in Orchiectomy
Dr. Daniel P. Petrylak
Oncology | Hematology Oncology

Yale University

5 Perryridge Rd, 
Greenwich, CT 
 (40.7 miles away)
203-863-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Petrylak is an Oncologist and a Hematologist Oncology provider in Greenwich, Connecticut. Dr. Petrylak is rated as an Elite provider by MediFind in Orchiectomy. His top areas of expertise are Prostate Cancer, Urothelial Cancer, Familial Prostate Cancer, Orchiectomy, and Gamma Knife Radiosurgery.

Advanced in Orchiectomy
Dr. William K. Oh
Oncology
Advanced in Orchiectomy
Dr. William K. Oh
Oncology

Yale University

35 Park St, 
New Haven, CT 
 (0.1 miles away)
203-785-4191
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Oh is an Oncologist in New Haven, Connecticut. Dr. Oh is rated as a Distinguished provider by MediFind in Orchiectomy. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Prostatectomy.

Experienced in Orchiectomy
Dr. Wei D. Xue
Hematology | Oncology
Experienced in Orchiectomy
Dr. Wei D. Xue
Hematology | Oncology

North Shore-Lij Medical PC

27005 76th Ave, 
New Hyde Park, NY 
 (55.4 miles away)
718-470-7000
Languages Spoken:
English
See accepted insurances

Wei Xue is a Hematologist and an Oncologist in New Hyde Park, New York. Dr. Xue is rated as an Elite provider by MediFind in Orchiectomy. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Nephrectomy, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hurwitz's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 8 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile